Key Takeaways
- Moderna shares closed 17.57% lower at $202.63 on October 22 after melanoma vaccine results appeared online ahead of their scheduled presentation.
- Intismeran plus Merck’s Keytruda reduced the risk of recurrence or death by 42% in Phase 3, compared with 49% in the earlier Phase 2b study.
- Investors now await the October 24 ESMO presentation and Moderna’s November 6 earnings, with attention on longer-term outcomes and commercial prospects.
Moderna Stock Slides Despite Positive Melanoma Results
Moderna shares fell sharply on October 22 after the early release of detailed results from its experimental personalized cancer vaccine. The stock closed at $202.63, down 17.57%, after touching an intraday low of $180.80—approximately 26% below its previous close. Nearly 50 million shares changed hands, more than three times the previous session’s volume. Selling continued after the closing bell, with shares finishing extended trading at $196.34, a further decline of 3.1%. Merck, Moderna’s development partner, ended the regular session approximately 1.8% lower.
The reaction followed positive clinical findings, but the central question for investors was whether the strength of those results justified expectations built during Moderna’s substantial rally this year.
Early Disclosure Brings Forward a Major Catalyst
Detailed trial findings appeared on an oncology news website two days before their planned presentation at the European Society for Medical Oncology (ESMO) congress in Madrid. Although the material was removed, the information circulated on social media. ESMO subsequently lifted the embargo, and Moderna and Merck released the detailed Phase 3 results on Thursday. This unexpected timing brought forward a closely watched catalyst, allowing investors to assess the size of the benefit more closely and reconsider assumptions about the treatment’s eventual market opportunity.
What the 42% Risk Reduction Means
The Phase 3 INTerpath-001 study evaluated intismeran autogene alongside Keytruda in patients whose high-risk melanoma had been completely removed surgically. The combination produced a hazard ratio of 0.58 for recurrence-free survival, representing a 42% relative reduction in the risk of cancer recurrence or death compared with Keytruda alone. This figure describes a relative effect over the study period and should not be interpreted as a 42-percentage-point improvement in survival or as proof that mortality alone fell by 42%. The combination also reduced the risk of distant metastasis or death by 38%. Overall survival data remain immature, although the companies reported a favorable trend, necessitating further follow-up to establish longer-term survival outcomes.
Why the Phase 2b Comparison Needs Context
One focus of the market reaction was the difference between the Phase 3 headline result and the 49% reduction in recurrence or death previously reported from the smaller Phase 2b study. The earlier figure came from approximately five years of follow-up in patients with resected stage III or IV melanoma, while the Phase 3 study covered a broader stage IIB–IV population and had a shorter follow-up period. These differences limit a direct comparison, and the numerical gap alone does not demonstrate that the treatment became less effective.
Analyst Support Meets Elevated Valuation Expectations
Analyst responses highlighted the gap between a favorable clinical assessment and a favorable share-price reaction. UBS suggested that elevated investor expectations could help explain the selling, while Jefferies described the findings as encouraging. These assessments support the interpretation that the decline reflected a reassessment of expectations following a powerful rally. Moderna remained up roughly 600% for the year despite Thursday’s fall, creating a demanding backdrop for any subsequent announcement.
ESMO Presentation and November Earnings Take Focus
The next major event is the formal ESMO presentation on October 24. Investors will look for a fuller discussion of the trial, the durability of benefit, and the implications of immature overall survival data. Moderna’s third-quarter results follow on November 6, providing another opportunity to examine financial performance, spending priorities, and management’s development plans. The commercial questions extend beyond clinical efficacy to regulatory timing, manufacturing execution, and the resources required to support a potential launch.
Conclusion
Moderna’s sell-off leaves investors weighing positive late-stage evidence against expectations accumulated during an exceptional rally. The upcoming ESMO presentation and November earnings will help determine whether the latest decline develops into a broader valuation reset or stabilizes as the market absorbs the full results.